- Home
- AGMH vs ONCO Comparison
AGMH vs ONCO Comparison
Compare AGMH & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- ONCO
- Stock Information
- Founded
- AGMH 2015
- ONCO 2018
- Country
- AGMH Hong Kong
- ONCO United States
- Employees
- AGMH N/A
- ONCO N/A
- Industry
- AGMH EDP Services
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- ONCO Health Care
- Exchange
- AGMH Nasdaq
- ONCO Nasdaq
- Market Cap
- AGMH 1.8M
- ONCO 1.8M
- IPO Year
- AGMH 2018
- ONCO 2022
- Fundamental
- Price
- AGMH $0.05
- ONCO $0.07
- Analyst Decision
- AGMH
- ONCO
- Analyst Count
- AGMH 0
- ONCO 0
- Target Price
- AGMH N/A
- ONCO N/A
- AVG Volume (30 Days)
- AGMH 73.4M
- ONCO 12.7M
- Earning Date
- AGMH 06-18-2025
- ONCO 05-19-2025
- Dividend Yield
- AGMH N/A
- ONCO N/A
- EPS Growth
- AGMH N/A
- ONCO N/A
- EPS
- AGMH N/A
- ONCO N/A
- Revenue
- AGMH $64,998,081.00
- ONCO $1,870,605.00
- Revenue This Year
- AGMH N/A
- ONCO N/A
- Revenue Next Year
- AGMH N/A
- ONCO N/A
- P/E Ratio
- AGMH N/A
- ONCO N/A
- Revenue Growth
- AGMH N/A
- ONCO N/A
- 52 Week Low
- AGMH $0.02
- ONCO $0.05
- 52 Week High
- AGMH $2.19
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- AGMH 36.92
- ONCO 31.80
- Support Level
- AGMH $0.04
- ONCO $0.05
- Resistance Level
- AGMH $0.08
- ONCO $0.08
- Average True Range (ATR)
- AGMH 0.01
- ONCO 0.01
- MACD
- AGMH 0.02
- ONCO 0.01
- Stochastic Oscillator
- AGMH 48.36
- ONCO 35.54
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.